Notably, the PI3K/AKT/MTOR pathway is a target of NVP-BGT226 as well as NVP-BEZ235 in native acute leukemia cells as verified in an immunoblot experiment for two patient samples with newly diagnosed acute leukemia (Additional file 2: Figure S1B, provided with the online version of the article). This evidence concerns the gene AKT1 and acute leukemia.